Response to Carboplatin and Paclitaxel in the treatment of hereditary breast ovarian cancer syndrome (HBOC): a case report

被引：0
|
作者：
Mehmood, Faisal [1 ]
Touseef, Mumtaz [2 ]
Ashraf, Amna [2 ]
Rai, Izza Ali [3 ]
机构：
[1] Combined Mil Hosp, Dept Radiol, Lahore, Pakistan
[2] Combined Mil Hosp, Dept Med, Lahore, Pakistan
[3] Combined Mil Hosp, Dept Vasc Surg, Lahore, Pakistan
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 12期
关键词：
Hereditary breast ovarian cancer; Breast cancer; Ovarian cancer; HBOC; BRCA; PALB2; Chemotherapy; Carboplatin; Paclitaxel; PREVALENCE; MUTATIONS;
D O I：
10.47391/JPMA.20059
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and results from inherent mutations in critical genes like a unique case of hereditary breast-ovarian cancer syndrome (HBOC) reported in Combined Military Hospital, Lahore, Pakistan. It was marked by pathogenic variants in RAD51D, PALB2, CHEK1, and TP53 genes. Remarkably, the patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. This dynamic treatment not only led to nearly complete remission of high-grade ovarian serous cancer but also triggered regression in grade-2 invasive ductal breast cancer after just a few rounds of chemotherapy. Consequently, what started as palliative care evolved into a curative triumph.
引用
收藏
页码：2184 / 2187
页数：4
相关论文
共 50 条
  • [31] Combination treatment with paclitaxel, carboplatin and cetuximab in maxillary sinus cancer: A case report
    Morimoto, Masahiro
    Takano, Masashi
    Sato, Takehiko
    Makino, Shujiroh
    ONCOLOGY LETTERS, 2024, 27 (03)
  • [32] Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?
    Higgins, RV
    Naumann, RW
    Gardner, J
    Hall, JB
    GYNECOLOGIC ONCOLOGY, 1999, 75 (03) : 464 - 467
  • [33] Paclitaxel and Carboplatin Treatment for Advanced Ovarian Cancer during Pregnancy
    Ramos, Jesus Ruiz
    Roma, Eva
    Palomar, Laura
    Poveda, Jose Luis
    CHEMOTHERAPY, 2013, 59 (05) : 344 - 345
  • [34] Spectrum of BRCA Mutations in Hereditary Breast and Ovarian Cancer (HBOC) within the Indian Context
    Jajodia, E.
    Chaudhary, P.
    Trivedi, N.
    Kamdar, P.
    Suthar, J.
    Chaudhary, S.
    Patel, S.
    Patel, D.
    Sharma, D.
    Arora, N.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S100 - S100
  • [35] Gynecologists' knowledge of and attitudes towards genetic counseling for hereditary breast and ovarian cancer (HBOC)
    Mehnert, A
    Bergelt, C
    Koch, U
    PSYCHO-ONCOLOGY, 2001, 10 (04) : S38 - S38
  • [36] Characterization of BRCA Genes' Variants in Turkish Hereditary Breast and Ovarian Cancer(HBOC) Patients
    Ates, E. A.
    Alavanda, C.
    Polat, H.
    Turkyilmaz, A.
    Soylemez, M. A.
    Geckinli, B. B.
    Guney, A. I.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 935 - 935
  • [37] CARBOPLATIN AND PACLITAXEL IN OVARIAN-CANCER
    OZOLS, RF
    SEMINARS IN ONCOLOGY, 1995, 22 (03) : 78 - 83
  • [38] Factors Associated with Genetic Testing Among Relatives of Individuals with Hereditary Breast and Ovarian Cancer Syndrome (HBOC): An integrative Review
    Robinson, Kathryn
    Underhill, Meghan
    NURSING RESEARCH, 2017, 66 (02) : E124 - E124
  • [39] Reversible posterior leukoencephalopathy syndrome following carboplatin and paclitaxel in cervical cancer: Case report
    Ouchane, Karima
    Bellefkih, Fatima Zahra
    Benchakroun, Nadia
    Bourhafour, Mouna
    Chekrine, Tarik
    Bouchbika, Zineb
    Jouhadi, Hassan
    Tawfiq, Nezha
    Sahraoui, Souha
    SAGE OPEN MEDICAL CASE REPORTS, 2024, 12
  • [40] Hereditary Breast- and Ovarian Cancer Syndrome
    Kiechle, M.
    GYNAKOLOGE, 2014, 47 (10): : 733 - 734
12345